Obsessive-Compulsive Disorder | Treatment Algorithms: Claims Data Analysis | US | 2024

Obsessive-compulsive disorder (OCD) is characterized by repeated intrusive thoughts, uncontrollable repetitive behaviors, or both. First-line OCD therapy commonly includes psychotherapy but may also include pharmacotherapy to relieve patient distress. Selective serotonin reuptake inhibitors (SSRIs), many of which are FDA-approved for OCD, are the first-line drug of choice in OCD management. Other agents, including serotonin / norepinephrine reuptake inhibitors (SNRIs), atypical antipsychotics, anxiolytics, and mood stabilizers, may also be used. Although the OCD therapy market is highly genericized, variation in both the presentation of this indication and patients’ response to treatment may warrant the use of branded agents, particularly in later lines of therapy. In this report, we use national patient-level claims data to explore the use of key therapies for OCD in both newly diagnosed and recently treated patients.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OCD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OCD patients?
• How have branded antidepressants (e.g., Trintellix [Lundbeck / Takeda]) and atypical antipsychotics (e.g., Vraylar [AbbVie]) been integrated into the treatment algorithm, and what is their source of business?
• What percentage of OCD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of OCD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients with OCD?

Markets covered: United States

Key companies: AbbVie, Lundbeck, Otsuka, Takeda, Johnson & Johnson Innovative Medicine, Axsome Therapeutics, Intra-Cellular Therapies, Alkermes, Vanda Pharmaceuticals

Key drugs: SSRIs, SNRIs, atypical antipsychotics, anxiolytics, benzodiazepines

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key features

Dashboard featuring interactive visuals, easy navigation, and expanded analyses.